According to large-scale glioblastoma genomics and clinical data from the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA), the main regulatory factor of m6A methylation, METTL3, shows differential expression in glioblastomas and is closely associated with disease progression (Chai et al., 2019). The gene discussed is METTL3; the disease is central nervous system cancer.